

DEC 22 2006

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



IN RE APPLICATION OF: Kiyoshi OKAMOTO, et al.

SERIAL NO: 10/593,811

GAU: 1632

FILED: September 22, 2006

EXAMINER:

FOR: USING NONHUMAN ANIMAL MODEL, METHOD OF MEASURING TRANSCRIPTION ACTIVITY METHOD OF MEASURING CELL QUANTITY AND METHOD OF MEASURING TUMOR VOLUME

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.

A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

Attached is a list of applicant's pending application(s), published application(s) or issued patent(s) which may be related to the present application. In accordance with the waiver of 37 CFR 1.98 dated September 21, 2004, copies of the cited pending applications are not provided. Cited published and/or issued patents, if any, are listed on the attached PTO form 1449.

A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION


Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBOLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon

James H. Knebel
Registration No. 22,630

Customer Number

22850

Tel (703) 413-3000
Fax (703) 413-2220
(OSMMN 05/03)

Form PTO 1449 (Modified)	U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO. 296514US0PCT	SERIAL NO. 10/593,811
LIST OF REFERENCES CITED BY APPLICANT		APPLICANT Kiyoshi OKAMOTO, et al.	
		FILING DATE September 22, 2006	GROUP 1632

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						
AM						
AN						

FOREIGN PATENT DOCUMENTS

/JH/	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO
/JH/	AO WO 03/106663 A1	12/24/2003	WIPO (with English abstract)		X
AP					
AQ					
AR					
AS					
AT					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)

/JH/	AU	K. YAMAGATA, et al., "Experimental study of lymphogenous peritoneal cancer dissemination: migration of fluorescent-labelled tumor cells in a rat model of mesenteric lymph vessel obstruction", JOURNAL OF EXPERIMENTAL CLINICAL CANCER RESEARCH 21, Vol. 19, No. 2, June 2000, 1 page (submitting abstract only).	
	AV	Robert H. SHOEMAKER, et al., "Targeting the HIF-1 α Signaling Pathway for Cancer Therapy", THE 7 TH INTERNATIONAL SYMPOSIUM ON CANCER CHEMOTHERAPY, December 2-3, 2002, Cover page, pages 2-4 and page 44.	
	AW	Masaki GOTO, et al., "Inhibitory Effect of E3330, a Novel Quinone Derivative Able to Suppress Tumor Necrosis Factor- α Generation, on Activation of Nuclear Factor- κ B", MOLECULAR PHARMACOLOGY, Vol. 49, No. 5, May 1996, Cover page and pages 860-873.	
	AX	Meng YANG, et al., "A Fluorescent Orthotopic Bone Metastasis Model of Human Prostate Cancer", CANCER RESEARCH, Vol. 59, No. 4, February 15, 1999, Cover page and pages 781-786.	
	AY	Kristen L. KUCHARCZUK, et al, "Fine-scale transgenic mapping of the MyoD core enhancer: MyoD is regulated by distinct but overlapping mechanisms in myotomal and non-myotomal muscle lineages", DEVELOPMENT, Volume 126, No. 9, May 1999, Cover page and pages 1957-1965.	
↓	AZ	Joseph SAMBROOK, "Protocol 8: Northern Hybridization", MOLECULAR CLONING, A LABORATORY MANUAL THIRD EDITION, 2001, 2 cover pages and pages 7.42-7.45.	<input type="checkbox"/> Additional References sheet(s) attached
Examiner	/Joanne Hama/	Date Considered	07/25/2008

*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.